Skip to main content
OpenTrials

Clinical trial condition

Neoplasms, Plasma Cell

Explore clinical trials studying Neoplasms, Plasma Cell. Study availability and eligibility vary by location and protocol.

2,606 public trials 547 recruiting studies
Refine in advanced search Browse all conditions

Neoplasms, Plasma Cell trial results

Completed

A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia

NCT03187262

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • Memorial Sloan-Kettering Cancer Center New York, United States
View Trial Details
Completed

A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain

NCT02946333

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Hospital Punta de Europa Algeciras, Andalusia, Spain
  • Hospital de Antequera Antequera, Andalusia, Spain
  • Hospital Reina Sofía Córdoba, Andalusia, Spain
  • Hospital Huercal Olvera Huercal Olvera, Andalusia, Spain
View all 65 locations
View Trial Details
Completed

A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT02963493

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Innovative Clinical Research Institute (ICRI) Whittier, California, United States
  • University of Florida Gainesville, Florida, United States
  • RUSH Chicago, Illinois, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 20 locations
View Trial Details
Completed

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT01647971

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +33 more
Locations
  • TG Therapeutics Investigational Trial Site Huntsville, Alabama, United States
  • TG Therapeutics Investigational Trial Site Jonesboro, Arkansas, United States
  • TG Therapeutics Investigational Trial Site Athens, Georgia, United States
  • TG Therapeutics Investigational Trial Site Macon, Georgia, United States
View Trial Details
Completed

A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

NCT04543305

Conditions
Acute Myeloid Leukemia, Blood Protein Disorders, Bone Marrow Diseases, +22 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Florida Cancer Specialists Lake Mary, Florida, United States
  • Florida Cancer Specialists Sarasota, Florida, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Completed

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

NCT01568866

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Providence St. Joseph Medical Center Burbank, California, United States
  • UCSD Moore Cancer Center La Jolla, California, United States
  • UCLA Medical Center Los Angeles, California, United States
  • Central Coast Medical Oncology Group Santa Maria, California, United States
View all 241 locations
View Trial Details

Related conditions